Literature DB >> 20194156

Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma.

Sumit Madan, Robert A Kyle, Philip R Greipp.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20194156      PMCID： PMC2843123          DOI： 10.4065/mcp.2009.0653

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  4 in total

1.  Plasma cell labeling index.

Authors:  Philip R Greipp; Shaji Kumar
Journal:  Methods Mol Med       Date:  2005

2.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

3.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

4.  Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.

Authors:  P R Greipp; J A Lust; W M O'Fallon; J A Katzmann; T E Witzig; R A Kyle
Journal:  Blood       Date:  1993-06-15       Impact factor: 22.113
  4 in total
  10 in total

Review 1.  Smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Ola Landgren; María-Victoria Mateos
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.

Authors:  Mohammed A Aljama; M Hasib Sidiqi; Arjun Lakshman; Angela Dispenzieri; Dragan Jevremovic; Morie A Gertz; Martha Q Lacy; Francis K Buadi; David Dingli; Eli Muchtar; Amie L Fonder; Suzanne R Hayman; Miriam A Hobbs; Wilson I Gonsalves; Rahma Warsame; Taxiarchis V Kourelis; Yi Lisa Hwa; Prashant Kapoor; Nelson Leung; Ronald S Go; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar
Journal:  Blood Adv       Date:  2018-11-27

3.  Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.

Authors:  Patrick W Mellors; Moritz Binder; Rhett P Ketterling; Patricia T Greipp; Linda B Baughn; Jess F Peterson; Dragan Jevremovic; Kathryn E Pearce; Francis K Buadi; Martha Q Lacy; Morie A Gertz; Angela Dispenzieri; Suzanne R Hayman; Prashant Kapoor; Wilson I Gonsalves; Yi L Hwa; Amie Fonder; Miriam Hobbs; Taxiarchis Kourelis; Rahma Warsame; John A Lust; Nelson Leung; Ronald S Go; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar
Journal:  Blood Adv       Date:  2020-05-26

4.  Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).

Authors:  Rashid Khan; Madhav Dhodapkar; Adam Rosenthal; Christoph Heuck; Xenofon Papanikolaou; Pingping Qu; Frits van Rhee; Maurizio Zangari; Yogesh Jethava; Joshua Epstein; Shmuel Yaccoby; Antje Hoering; John Crowley; Nathan Petty; Clyde Bailey; Gareth Morgan; Bart Barlogie
Journal:  Haematologica       Date:  2015-05-28       Impact factor: 9.941

Review 5.  Dilemmas in treating smoldering multiple myeloma.

Authors:  Inhye E Ahn; Sham Mailankody; Neha Korde; Ola Landgren
Journal:  J Clin Oncol       Date:  2014-11-24       Impact factor: 44.544

6.  A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.

Authors:  T E Witzig; K M Laumann; M Q Lacy; S R Hayman; A Dispenzieri; S Kumar; C B Reeder; V Roy; J A Lust; M A Gertz; P R Greipp; H Hassoun; S J Mandrekar; S V Rajkumar
Journal:  Leukemia       Date:  2012-08-20       Impact factor: 11.528

Review 7.  Smoldering multiple myeloma requiring treatment: time for a new definition?

Authors:  Angela Dispenzieri; A Keith Stewart; Asher Chanan-Khan; S Vincent Rajkumar; Robert A Kyle; Rafael Fonseca; Prashant Kapoor; P Leif Bergsagel; Arleigh McCurdy; Morie A Gertz; Martha Q Lacy; John A Lust; Stephen J Russell; Steven R Zeldenrust; Craig Reeder; Vivek Roy; Francis Buadi; David Dingli; Suzanne R Hayman; Nelson Leung; Yi Lin; Joseph Mikhael; Shaji K Kumar
Journal:  Blood       Date:  2013-10-21       Impact factor: 22.113

8.  Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.

Authors:  M Hasib Sidiqi; Mohammed A Aljama; Dragan Jevremovic; William G Morice; Michael Timm; Francis K Buadi; Rahma Warsame; Martha Q Lacy; Angela Dispenzieri; David Dingli; Wilson I Gonsalves; Shaji Kumar; Prashant Kapoor; Taxiarchis Kourelis; Nelson Leung; William J Hogan; Morie Gertz
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

9.  The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.

Authors:  Eileen M Boyle; Shayu Deshpande; Ruslana Tytarenko; Cody Ashby; Yan Wang; Michael A Bauer; Sarah K Johnson; Christopher P Wardell; Sharmilan Thanendrarajan; Maurizio Zangari; Thierry Facon; Charles Dumontet; Bart Barlogie; Arnaldo Arbini; Even H Rustad; Francesco Maura; Ola Landgren; Fenghuang Zhan; Frits van Rhee; Carolina Schinke; Faith E Davies; Gareth J Morgan; Brian A Walker
Journal:  Nat Commun       Date:  2021-01-12       Impact factor: 14.919

10.  Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms.

Authors:  María A Vasco-Mogorrón; José A Campillo; Adela Periago; Valentin Cabañas; Mercedes Berenguer; María C García-Garay; Lourdes Gimeno; María F Soto-Ramírez; María D Martínez-Hernández; Manuel Muro; Alfredo Minguela
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.